Join to View Full Profile
2301 Erwin RdDurham, NC 27705
Phone+1 610-442-9029
Fax+1 919-620-4921
Dr. Swaminathan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 2015 - 2019- Duke University HospitalResidency, Internal Medicine, 2012 - 2015
Case Western Reserve University School of MedicineClass of 2012
Certifications & Licensure
NC State Medical License 2012 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry.Aparna C Swaminathan, Jeremy M Weber, Jamie L Todd, Scott M Palmer, Megan L Neely
Respiratory Research. 2025-02-28 - Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil.Aparna C Swaminathan, Amber Meservey, Alice Parish, Cynthia L Green, Kishan Parikh
JHLT Open. 2024-11-01 - Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease.Aparna C Swaminathan, Molly McFatrich, Laura Mkumba, Lauren Wright, Carrie A Redlich
Respiratory Research. 2024-10-15
Grant Support
- Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung DiseasesDUKE UNIVERSITY2023–2028
- Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung DiseasesDUKE UNIVERSITY2023–2028
- Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung DiseasesDUKE UNIVERSITY2023–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
